Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial

Background: Intestinal microbiota restoration can be achieved by complementing a subject's perturbed microbiota with that of a healthy donor. RecurrentClostridioides difficileinfection (rCDI) is one key application of such treatment. Another emerging application of interest is reducing antibiot...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Microbiome 2020-08, Vol.8 (1), p.125-16, Article 125
Hauptverfasser:	Kwak, Suryang, Choi, JooHee, Hink, Tiffany, Reske, Kimberly A., Blount, Kenneth, Jones, Courtney, Bost, Margaret H., Sun, Xiaoqing, Burnham, Carey-Ann D., Dubberke, Erik R., Dantas, Gautam
Format:	Artikel
Sprache:	eng
Schlagworte:	Abundance Aged Antibiotic resistance Antibiotic-resistant organisms Antibiotics Bacteria - genetics Bacteria - isolation & purification Biodiversity Clinical trials Clostridioides difficile infection Colonization Digestive system Double-Blind Method Drug dosages Drug resistance Drug Resistance, Microbial - genetics Feces Female Gastrointestinal Microbiome - genetics Gastrointestinal tract Genomes Humans Intestinal microflora Intestine Life Sciences & Biomedicine Male Metagenomics Microbiology Microbiome Microbiomes Microbiota Microbiota-based therapy Middle Aged Pathogens Patients Placebo Recurrent infection Resistome Science & Technology Staphylococcus infections Success Taxonomy Transplantation Transplants & implants Whole genome sequencing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!